

Grifols invites you to join this satellite symposium at the 7th Congress of the European Academy of Neurology (EAN 2021) entitled “AMBAR: Plasma Exchange plus albumin replacement as an innovative treatment for Alzheimer’s disease”.

Research into Alzheimer’s disease (AD) at Grifols began in 2004 with a small clinical trial on the potential of plasma exchange with albumin to slow the progression of the disease in the treatment of patients in mild and moderate stages. More than a decade later, we are pleased to present the findings of AMBAR, the latest study in the program. The complete efficacy and safety results along with the scientific rationale supporting the medical procedure will be discussed.


Satellite Symposium at the 7th EAN Congress

AMBAR
***Plasma Exchange plus albumin
replacement as an innovative treatment
for Alzheimer’s disease***

Monday, June 21st, 2021
12.15h - 13.15h
Room Amsterdam

**Symposium sponsored by Grifols
at the EAN 2021 VIRTUAL MEETING**

*Monday, June 21st, 2021
12.15h - 13.15h*



AMBAR

***Plasma Exchange plus albumin replacement as
an innovative treatment for Alzheimer's disease***

- Chair:** *Mercè Boada, M.D., Ph.D. Fundació ACE, Universitat
Internacional de Catalunya, Barcelona, Spain*
- 5 min** **Introduction to AMBAR**
Mercè Boada, M.D., Ph.D.
- 10 min** **Plasma exchange in neurology: a long experience
of a safe procedure**
*Miguel Lozano, M.D., Ph.D., Clínic University Hospital,
Barcelona, Spain*
- 15 min** **AMBAR: A multi-mechanism approach for AD**
*Montserrat Costa, Ph.D., Grifols Bioscience Research Group,
Spain*
- 20 min** **AMBAR: primary results**
*Javier Olazarán, M.D., Gregorio Marañón University
Hospital, Madrid, Spain*
- 10 min** **Q&As. Discussion**
All

GRIFOLS